TARRYTOWN, N.Y., Sept. 17, 2019 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that
the company was added to the Dow Jones Sustainability World Index
(DJSI World) for the first time. Regeneron is one of only four
companies in the biotechnology sector to be included on the DJSI
World list. DJSI World is a leading global index comprised of
corporate leaders in environmental, social and governance (ESG)
practices, which recognizes the top 10 percent most sustainable
companies in each industry.
"At Regeneron, our mission is to harness the power of science to
help people with serious diseases. Our commitment to sustainable
business practices is critical to delivering on this mission and to
positively impacting society," said Leonard
S. Schleifer, M.D., Ph.D., President and Chief Executive
Officer at Regeneron. "Corporate responsibility at Regeneron means
many things, including continuing to invest in cutting-edge
science, ensuring patient access to medicines, sustaining a culture
of integrity, and safeguarding a sustainable future through
thoughtful environmental practices and supporting the next
generation of scientific innovators."
DJSI World is considered the gold standard for measuring
corporate ESG practices. It is published by S&P Dow Jones
Indices, one of the world's leading index providers, together with
RobecoSAM, which specializes in ESG data and benchmarking. This
year, more than 4,500 global companies were invited to participate
in the evaluation process.
"We are excited to be recognized on DJSI World alongside other
global leaders in corporate responsibility," said Hala Mirza, Senior Vice President of Corporate
Communications and Citizenship at Regeneron. "Over the last few
years, we have increased transparency and reporting while advancing
our sustainability practices, and we look forward to continuing
these efforts in years to come."
Regeneron publishes an annual Responsibility Report that
provides an overview of our progress on sustainability. In addition
to DJSI World, Regeneron has received a number of other
recognitions, including The Civic 50, a list of the 50 most
community-minded companies in the United
States; FTSE4Good Index, a list of companies with leading
environmental, social and governance practices; Science #1
Top Employer in the biopharma industry; and Fortune 100 Best
Companies to Work For. The company's most significant philanthropic
commitments are in the area of science education, including the
Regeneron Science Talent Search, the nation's most prestigious
science and math competition for high school seniors.
About Regeneron Pharmaceuticals, Inc.
Regeneron
(NASDAQ: REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for 30 years by physician-scientists, our unique
ability to repeatedly and consistently translate science into
medicine has led to seven FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye disease, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, infectious diseases,
pain and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, such as
VelocImmune® which produces optimized fully-human
antibodies, and ambitious research initiatives such as the
Regeneron Genetics Center, which is conducting one of the largest
genetics sequencing efforts in the world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Regeneron Contacts:
Media Relations
Alexandra
Bowie
Tel : +1 (914) 847-3407
Alexandra.bowie@regeneron.com
Investor Relations
Justin
Holko
Tel: +1 (914) 847-7786
Justin.Holko@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-debuts-on-prestigious-dow-jones-sustainability-world-index-of-most-sustainable-companies-300919191.html
SOURCE Regeneron Pharmaceuticals, Inc.